Aura Renew Acq Regulatory News (ARA)

28 Jun 2007 07:01

Ardana PLC28 June 2007 ARDANA BOARD CHANGES Edinburgh, UK, 28 June, 2007: Ardana, the company focused on improving humanreproductive health, today announces the appointment of Dr Chris Moyses to itsBoard of Directors as a non-executive director and the retirement from the Boardof Ian Kent after seven years' service. Both changes are with immediate effect. Dr Moyses is a member of the Royal College of Physicians of London and iscurrently Chief Medical Officer and director of Argenta Discovery Limited andthe non- executive chairman of Senexis Limited. His previous positions includeResearch and Development Director of Pharmagene plc, Chief Medical Officer anddirector of Oxford GlycoSciences plc and Vice President of Clinical andRegulatory Affairs at Amylin Europe. Dr Moyses will also become a member of Ardana's Nominations and CorporateGovernance Committee, Audit Committee and Remuneration Committee. With reference to paragraphs 9.6.13 (1)-(6) of the FSA's Listing Rules, thereare no other disclosures required. Ian Kent joined the Ardana Board as a founder non executive director andChairman in 2000. He relinquished the role of non executive Chairman in 2004.Huw Jones replaces Ian as the Chairman of the Remuneration Committee. Maureen Lindsay, CEO of Ardana, said: "We are very grateful for the support and direction that Ian has given to Ardanasince its inception and we wish him every success for the future. We welcomeChris to Ardana. He brings considerable pharmaceutical medical and regulatoryknowledge and experience to our Board that will be invaluable to us as we expandour business and development product pipeline." For more information contact: Ardana Financial DynamicsMaureen Lindsay (corporate/financial media relations)Tel: + 44 (0) 131 226 8550 Julia Phillips/John Gilbert Tel: +44 (0)20 7831 3113 About Ardana Ardana plc is a pharmaceutical company focused on the discovery, development andmarketing of innovative products to improve human reproductive health, a $25.5billion market. Since its foundation, Ardana has maintained a broad and balanced portfolio tomanage risk and actively pursues product and technology in-licensing andoutlicensing to maintain a robust pipeline. Ardana's lead products are summarised below: • Emselex(R), a once a day treatment for the symptoms of overactive bladder syndrome which Ardana has exclusive UK marketing and promotion rights and is being distributed in collaboration with Novartis UK Limited; • Striant(TM) SR, a testosterone replacement therapy that has been launched by Ardana through its own sales force in the UK and through marketing partners in certain European countries, as a treatment for men with confirmed hypogonadism; • Teverelix LA, in development for three initial indications (prostate cancer, benign prostatic hyperplasia and endometriosis); • Testosterone Cream, a trans dermal testosterone delivery system in development for the treatment of male hypogonadism, in Phase II trials; • Invicorp, an injectable combination drug treatment for erectile dysfunction, for which Ardana has marketing and manufacturing rights in Europe. • ARD-07 a growth hormone secretagogue in late stage development for the diagnosis of hormone deficiency In addition, Ardana has a strong portfolio of follow-on products in development.Ardana is listed on the Main Market of the London Stock Exchange. For further information please see www.ardana.co.uk This information is provided by RNS The company news service from the London Stock Exchange